These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 22934095)

  • 1. Cytokine-neuroantigen fusion proteins as a new class of tolerogenic, therapeutic vaccines for treatment of inflammatory demyelinating disease in rodent models of multiple sclerosis.
    Mannie MD; Blanchfield JL; Islam SM; Abbott DJ
    Front Immunol; 2012; 3():255. PubMed ID: 22934095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A GMCSF-neuroantigen fusion protein is a potent tolerogen in experimental autoimmune encephalomyelitis (EAE) that is associated with efficient targeting of neuroantigen to APC.
    Blanchfield JL; Mannie MD
    J Leukoc Biol; 2010 Mar; 87(3):509-21. PubMed ID: 20007248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A fusion protein consisting of IL-16 and the encephalitogenic peptide of myelin basic protein constitutes an antigen-specific tolerogenic vaccine that inhibits experimental autoimmune encephalomyelitis.
    Mannie MD; Abbott DJ
    J Immunol; 2007 Aug; 179(3):1458-65. PubMed ID: 17641011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-2/neuroantigen fusion proteins as antigen-specific tolerogens in experimental autoimmune encephalomyelitis (EAE): correlation of T cell-mediated antigen presentation and tolerance induction.
    Mannie MD; Clayson BA; Buskirk EJ; DeVine JL; Hernandez JJ; Abbott DJ
    J Immunol; 2007 Mar; 178(5):2835-43. PubMed ID: 17312127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A GM-CSF-neuroantigen tolerogenic vaccine elicits inefficient antigen recognition events below the CD40L triggering threshold to expand CD4
    Moorman CD; Bastian AG; DeOca KB; Mannie MD
    J Neuroinflammation; 2020 Jun; 17(1):180. PubMed ID: 32522287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GM-CSF-neuroantigen fusion proteins reverse experimental autoimmune encephalomyelitis and mediate tolerogenic activity in adjuvant-primed environments: association with inflammation-dependent, inhibitory antigen presentation.
    Islam SM; Curtis AD; Taslim N; Wilkinson DS; Mannie MD
    J Immunol; 2014 Sep; 193(5):2317-29. PubMed ID: 25049359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experimental autoimmune encephalomyelitis in Lewis rats: IFN-beta acts as a tolerogenic adjuvant for induction of neuroantigen-dependent tolerance.
    Mannie MD; Abbott DJ; Blanchfield JL
    J Immunol; 2009 May; 182(9):5331-41. PubMed ID: 19380780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A GMCSF-Neuroantigen Tolerogenic Vaccine Elicits Systemic Lymphocytosis of CD4
    Moorman CD; Curtis AD; Bastian AG; Elliott SE; Mannie MD
    Front Immunol; 2018; 9():3119. PubMed ID: 30687323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroantigen-specific, tolerogenic vaccines: GM-CSF is a fusion partner that facilitates tolerance rather than immunity to dominant self-epitopes of myelin in murine models of experimental autoimmune encephalomyelitis (EAE).
    Abbott DJ; Blanchfield JL; Martinson DA; Russell SC; Taslim N; Curtis AD; Mannie MD
    BMC Immunol; 2011 Dec; 12():72. PubMed ID: 22208499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IFN-β Facilitates Neuroantigen-Dependent Induction of CD25+ FOXP3+ Regulatory T Cells That Suppress Experimental Autoimmune Encephalomyelitis.
    Wang D; Ghosh D; Islam SM; Moorman CD; Thomason AE; Wilkinson DS; Mannie MD
    J Immunol; 2016 Oct; 197(8):2992-3007. PubMed ID: 27619998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytokine-neuroantigen fusion proteins: new tools for modulation of myelin basic protein (MBP)-specific T cell responses in experimental autoimmune encephalomyelitis.
    Mannie MD; Devine JL; Clayson BA; Lewis LT; Abbott DJ
    J Immunol Methods; 2007 Jan; 319(1-2):118-32. PubMed ID: 17188704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolerogenic vaccines for Multiple sclerosis.
    Mannie MD; Curtis AD
    Hum Vaccin Immunother; 2013 May; 9(5):1032-8. PubMed ID: 23357858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Class II-restricted T cell responses in Theiler's murine encephalomyelitis virus (TMEV)-induced demyelinating disease. III. Failure of neuroantigen-specific immune tolerance to affect the clinical course of demyelination.
    Miller SD; Gerety SJ; Kennedy MK; Peterson JD; Trotter JL; Tuohy VK; Waltenbaugh C; Dal Canto MC; Lipton HL
    J Neuroimmunol; 1990 Jan; 26(1):9-23. PubMed ID: 1688446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of experimental encephalomyelitis with a novel chimeric fusion protein of myelin basic protein and proteolipid protein.
    Elliott EA; McFarland HI; Nye SH; Cofiell R; Wilson TM; Wilkins JA; Squinto SP; Matis LA; Mueller JP
    J Clin Invest; 1996 Oct; 98(7):1602-12. PubMed ID: 8833909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-Zone IL-2 Signaling: Fusion Proteins Containing Linked CD25 and IL-2 Domains Sustain Tolerogenic Vaccination
    DeOca KB; Moorman CD; Garcia BL; Mannie MD
    Front Immunol; 2020; 11():541619. PubMed ID: 33072087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of MS-like disease by a multi epitope protein is mediated by induction of CD11c
    Kaushansky N; Kaminitz A; Allouche-Arnon H; Ben-Nun A
    J Neuroimmunol; 2019 Aug; 333():476953. PubMed ID: 31108399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ROS-Scavenging Lignin-Based Tolerogenic Nanoparticle Vaccine for Treatment of Multiple Sclerosis.
    Phan NM; Nguyen TL; Shin H; Trinh TA; Kim J
    ACS Nano; 2023 Dec; 17(24):24696-24709. PubMed ID: 38051295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccines for multiple sclerosis: progress to date.
    Correale J; Farez M; Gilmore W
    CNS Drugs; 2008; 22(3):175-98. PubMed ID: 18278975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of EAE by tolerogenic vaccination with PEGylated antigenic peptides.
    Pfeil J; Simonetti M; Lauer U; von Thülen B; Durek P; Poulsen C; Pawlowska J; Kröger M; Krähmer R; Leenders F; Hoffmann U; Hamann A
    Ther Adv Chronic Dis; 2021; 12():20406223211037830. PubMed ID: 34408824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T cell-depleted splenocytes from mice pre-immunized with neuroantigen in incomplete Freund's adjuvant involved in protection from experimental autoimmune encephalomyelitis.
    Zheng H; Zhang H; Liu F; Qi Y; Jiang H
    Immunol Lett; 2014; 157(1-2):38-44. PubMed ID: 24220208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.